TUCSON, Ariz., Aug. 10, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023.
"Throughout the quarter, we've significantly advanced our Wave Program," stated Jack Phillips, CEO of Accelerate Diagnostics, Inc. "Our recent achievements underscore our commitment to delivering a Wave pre-clinical positive blood culture study by year-end. Moreover, we're pleased with the ongoing progress of our BD partnership, resulting in the strongest quarter for US contracted instruments since 2021."
Second Quarter 2023 Operating Highlights:
Second Quarter 2023 Financial Highlights:
Year-to-date Financial 2023 Highlights
The Company is finalizing its analysis of the accounting for the Restructuring Transactions.
All share and per share amounts have been retroactively adjusted for all periods presented to reflect the reverse stock split effected on July 11th, 2023.
Full financial results for the quarter ended June 30, 2023 will be filed on Form 10-Q through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov
Audio Webcast and Conference Call Today at 4:30 p.m. Eastern Time
To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 4614555. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 8685802 until August 31, 2023.
This conference call will also be webcast and can be accessed from the company's website at ir.axdx.com. A replay of the audio webcast will be available until August 31, 2023.
Non-GAAP Financial Measures
This press release contains certain financial measures that are not recognized measures under accounting principles generally accepted in the United States of America ("GAAP"), which include SG&A, R&D, and operating income (loss) amounts excluding stock-based compensation expenses.
Our management and board of directors use expenses excluding the cost of stock-based compensation (net of forfeitures) to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short-term and long-term operating and financing plans. Accordingly, we believe that expenses excluding the cost of stock-based compensation provides useful information for investors in understanding and evaluating our operating results in the same manner as our management and our board of directors. Expenses excluding the cost of stock-based compensation is a non-GAAP financial measure and should be considered in addition to, not as superior to, or as a substitute for, SG&A expenses, R&D expenses, and operating income (loss) reported in accordance with GAAP. The following tables present a reconciliation of SG&A expenses, R&D expenses and operating income (loss) excluding stock-based compensation to comparable GAAP measures for the periods indicated:
Three Months Ended June 30, | Six Months Ended June 30, | |||
(in thousands) | (in thousands) | |||
2023 | 2022 | 2023 | 2022 | |
Sales, General and Administrative | $ 7,564 | $ 11,493 | $ 17,669 | $ 22,167 |
Non-cash equity-based compensation | 1,299 | 3,204 | 1,159 | 5,646 |
Sales, general and administrative less | $ 6,266 | $ 8,289 | $ 16,510 | $ 16,521 |
Three Months Ended June 30, | Six Months Ended June 30, | |||
(in thousands) | (in thousands) | |||
2023 | 2022 | 2023 | 2022 | |
Research and Development | $ 5,820 | $ 7,576 | $ 12,788 | $ 13,600 |
Non-cash equity-based | 256 | 539 | 861 | 901 |
Research and development less non- | $ 5,563 | $ 7,037 | $ 11,927 | $ 12,699 |
Three Months Ended June 30, | Six Months Ended June 30, | |||
(in thousands) | (in thousands) | |||
2023 | 2022 | 2023 | 2022 | |
Loss from operations | $ (12,585) | $ (17,989) | $ (28,647) | $ (33,884) |
Non-cash equity-based | 1,653 | 3,971 | 2,208 | 6,950 |
Loss from operations less non-cash | $ (10,932) | $ (14,018) | $ (26,439) | $ (26,934) |
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
"Accelerate Diagnostics" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc. Any trade, product or service name referenced in this document using the name "Accelerate" is a trademark and/or property of Accelerate Diagnostics, Inc. All other company and product names may be trademarks, registered trademarks, or service marks of the companies with which they are associated.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward-looking or may have forward-looking implications. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2023, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
ACCELERATE DIAGNOSTICS, INC. | ||
June 30, | December 31, | |
2023 | 2022 | |
Unaudited | ||
ASSETS | ||
Current assets: | ||
Cash and cash equivalents | $29,282 | $34,905 |
Investments | 1,423 | 10,656 |
Trade accounts receivable, net | 2,342 | 2,416 |
Inventory | 5,106 | 5,194 |
Prepaid expenses | 1,274 | 818 |
Other current assets | 2,812 | 2,025 |
Total current assets | 42,239 | 56,014 |
Property and equipment, net | 2,896 | 3,478 |
Finance lease assets, net | 2,091 | 2,422 |
Operating lease right of use assets, net | 1,527 | 1,859 |
Other non-current assets | 1,125 | 1,242 |
Total assets | $49,878 | $65,015 |
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
Current liabilities: | ||
Accounts payable | $4,033 | $4,501 |
Accrued liabilities | 3,229 | 2,682 |
Accrued interest | 348 | 472 |
Deferred revenue | 478 | 547 |
Current portion of convertible notes | 726 | 56,413 |
Finance lease, current | 1,180 | 1,113 |
Operating lease, current | 936 | 829 |
Derivative liability | 42,786 | — |
Total current liabilities | 53,716 | 66,557 |
Finance lease, non-current | 375 | 782 |
Operating lease, non-current | 1,064 | 1,545 |
Other non-current liabilities | 1,097 | 874 |
Accrued interest related-party | — | 663 |
Long-term debt related-party | — | 16,858 |
Convertible notes | 32,289 | — |
Total liabilities | $88,541 | $87,279 |
Stockholders' deficit: | ||
Preferred shares, $0.001 par value; | ||
5,000,000 preferred shares authorized with no shares issued and outstanding on | — | — |
Common stock, $0.001 par value; | ||
450,000,000 common shares authorized with 14,357,953 shares issued and | 14 | 10 |
Contributed capital | 657,057 | 630,432 |
Treasury stock | (45,067) | (45,067) |
Accumulated deficit | (650,014) | (607,239) |
Accumulated other comprehensive loss | (653) | (400) |
Total stockholders' deficit | (38,663) | (22,264) |
Total liabilities and stockholders' deficit | $49,878 | $65,015 |
See accompanying notes to condensed consolidated financial statements. | ||
ACCELERATE DIAGNOSTICS, INC. | |||||
Three Months Ended | Six Months Ended | ||||
June 30, | June 30, | June 30, | June 30, | ||
2023 | 2022 | 2023 | 2022 | ||
Net sales | $2,921 | $3,861 | $5,733 | $6,820 | |
Cost of sales | 2,122 | 2,781 | 3,923 | 4,937 | |
Gross profit | 799 | 1,080 | 1,810 | 1,883 | |
Costs and expenses: | |||||
Research and development | 5,820 | 7,576 | 12,788 | 13,600 | |
Sales, general and administrative | 7,564 | 11,493 | 17,669 | 22,167 | |
Total costs and expenses | 13,384 | 19,069 | 30,457 | 35,767 | |
Loss from operations | (12,585) | (17,989) | (28,647) | (33,884) | |
Other (expense) income: | |||||
Interest expense | (1,175) | (713) | (1,593) | (1,630) | |
Interest expense related-party | (804) | — | (1,817) | — | |
(Loss) gain on extinguishment of debt | (6,550) | 199 | (6,550) | 3,565 | |
(Loss) on financial instruments | (5,030) | — | (5,030) | — | |
Foreign currency exchange gain | 25 | 31 | 258 | 40 | |
Interest income | 255 | 56 | 675 | 78 | |
Other income (expense), net | 40 | (107) | 85 | (157) | |
Total other (expense) income, net | (13,239) | (534) | (13,972) | 1,896 | |
Net loss before income taxes | (25,824) | (18,523) | (42,619) | (31,988) | |
Provision for income taxes | (156) | — | (156) | — | |
Net loss | $(25,980) | $(18,523) | $(42,775) | $(31,988) | |
Basic and diluted net loss per share | $(2.36) | $(2.43) | $(4.11) | $(4.44) | |
Weighted average shares outstanding | 11,009 | 7,623 | 10,420 | 7,200 | |
Other comprehensive loss: | |||||
Net loss | $(25,980) | $(18,523) | $(42,775) | $(31,988) | |
Net unrealized gain (loss) on debt securities available-for-sale | 4 | (39) | 28 | (132) | |
Foreign currency translation adjustment | (26) | (161) | (281) | (240) | |
Comprehensive loss | $(26,002) | $(18,723) | $(43,028) | $(32,360) | |
See accompanying notes to condensed consolidated financial statements. | |||||
ACCELERATE DIAGNOSTICS, INC. | ||
Six Months Ended | ||
June 30, | June 30, | |
2023 | 2022 | |
Cash flows from operating activities: | ||
Net loss | $(42,775) | $(31,988) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 1,617 | 1,435 |
Amortization of investment discount | — | 79 |
Equity-based compensation | 2,208 | 6,950 |
Amortization of debt discount and issuance costs | 692 | 284 |
Amortization of debt discount related-party | 1,033 | — |
Loss on disposal of property and equipment | 68 | 283 |
Unrealized (gain) loss on equity investments | (90) | 157 |
Loss (gain) on extinguishment of debt | 6,550 | (3,565) |
Loss on derivative | 5,030 | — |
(Increase) decrease in assets: | ||
Contributions to deferred compensation plan | — | (110) |
Accounts receivable | 74 | (615) |
Inventory | (30) | (416) |
Prepaid expense and other | (78) | (719) |
Increase (decrease) in liabilities: | ||
Accounts payable | (451) | 658 |
Accrued liabilities and other | 125 | 2,288 |
Accrued interest | 900 | (159) |
Accrued interest from related-party | 784 | — |
Deferred revenue and income | (69) | (116) |
Deferred compensation | 223 | (51) |
Net cash used in operating activities | (24,189) | (25,605) |
Cash flows from investing activities: | ||
Purchases of equipment | (167) | (447) |
Purchase of marketable securities | — | (27,504) |
Maturities of marketable securities | 9,291 | 18,738 |
Net cash provided (used) by investing activities | 9,124 | (9,213) |
Cash flows from financing activities: | ||
Common stock to related party | 4,000 | — |
Payments on finance leases | (540) | (424) |
Proceeds from exercise of options | — | 7 |
Proceeds from issuance of common stocks under employee purchase plan | — | 137 |
Proceeds from issuance of convertible notes | 10,000 | — |
Transaction costs related to debt and equity issuance | (3,731) | — |
Net cash (used) provided by financing activities | 9,729 | (280) |
Effect of exchange rate on cash | (287) | (219) |
Decrease in cash and cash equivalents | (5,623) | (35,317) |
Cash and cash equivalents, beginning of period | 34,905 | 39,898 |
Cash and cash equivalents, end of period | $29,282 | $4,581 |
Non-cash investing activities: | ||
Net transfer of instruments from inventory to property and equipment | $88 | $202 |
Non-cash financing activities: | ||
Extinguishment of 2.50% Convertible Senior Notes (the "2.5% Notes") through | $— | $10,180 |
Capital contribution from the exchange of secured note and accrued interest through | $25,363 | $— |
Loss from the exchange of secured note and accrued interest through the issuance of | $6,059 | $— |
Capital contribution from the issuance of put option with related party | $1,336 | $— |
Exchange of 2.5% Notes and accrued interest for 5.0% Convertible Senior Notes (the | $56,893 | $— |
Debt premium on issuance of 5.0% Notes | $6,023 | $— |
Bifurcated derivative liability | $38,160 | $— |
Supplemental cash flow information: | ||
Interest paid | $— | $1,506 |
See accompanying notes to condensed consolidated financial statements. | ||
| Last Trade: | US$1.65 |
| Daily Change: | -0.02 -1.20 |
| Daily Volume: | 35,801 |
| Market Cap: | US$39.070M |
November 07, 2024 September 30, 2024 August 08, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
